AMAPEX ENVIRONEMENT SLU

Their core work

AMAPEX ENVIRONEMENT is a Barcelona-based environmental technology SME specializing in biological treatment of industrial wastewater, particularly effluents that conventional chemical or physical methods cannot adequately treat — known as "recalcitrant" wastewaters. Their flagship technology, RIBATI, uses bacterial processes to break down persistent pollutants in industrial discharge streams. The company followed a textbook SME Instrument path: a Phase 1 feasibility study in 2017 confirmed the concept, followed by a much larger Phase 2 project in 2020 to develop and commercialize the solution. Their work sits at the intersection of industrial microbiology and environmental compliance, targeting industries under pressure to clean up difficult effluent streams.

What they specialise in

How they've shifted over time

AMAPEX shows no shift in thematic focus — both projects carry the identical title and address the same problem. What evolved is their stage of development: the 2017 project was a small feasibility assessment (SME Phase 1, €50k), while the 2020 project is a full-scale innovation and market deployment effort (SME Phase 2, €717k), roughly 14x larger in funding. This progression strongly suggests the feasibility study validated the technology and business case, unlocking the larger investment. The trajectory is linear commercialization rather than diversification.

AMAPEX is on a commercialization path for a single proprietary biotreatment technology, suggesting future collaboration opportunities would likely involve industrial pilots, scale-up partnerships, or distribution arrangements rather than open-ended research.

How they like to work

AMAPEX has operated exclusively through the SME Instrument — a funding scheme designed for single companies, not consortia — so they have no recorded consortium partners in H2020. This indicates they work independently rather than as part of multi-partner research networks. For future collaborators, this means AMAPEX is more likely to seek bilateral technology licensing or pilot partnerships with industrial end-users than to join large research consortia.

AMAPEX has no recorded consortium partners across their two H2020 projects, as both were SME Instrument grants designed for solo company applicants. Their European network, if any, is not visible through H2020 participation data.

What sets them apart

AMAPEX appears to be a focused deep-tech SME with a single proprietary technology — bacterial treatment of recalcitrant industrial wastewaters — rather than a broad environmental consultancy. Their ability to secure both Phase 1 and Phase 2 SME Instrument funding for the same technology suggests a credible proof of concept and a defensible innovation. For industrial buyers or technology investors, they represent a potential single-source supplier of a niche biotreatment solution that addresses effluents most competitors cannot handle.

Highlights from their portfolio

• RIBATI
  The Phase 2 grant (2020–2022, €717,854) is the largest single EU investment in this company and represents the full commercial development of their core bacterial wastewater technology — the clearest signal of what AMAPEX is actually building.
• RIBATI
  The Phase 1 project (2017–2018, €50,000) is notable as the validation step that unlocked Phase 2 funding, confirming the technology passed EU feasibility scrutiny and has a credible market case.